Companies › Vaccinex
2 active drug programs in 4 registered trials: 4 Phase 1; Oncology; next expected readout Dec 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Avelumab Programmed cell death 1 ligand 1 other | CD274 | Phase 1 | Metastatic Pancreatic Adenocarcinoma | Dec 2028 |
| Pepinemab Semaphorin-4D inhibitor | SEMA4D | Phase 1 | Metastatic Pancreatic Adenocarcinoma; Squamous Cell Carcinoma of the Head and Neck; Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Dec 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03690986 | Pepinemab | Phase 1 | Squamous Cell Carcinoma of the Head and Neck | Oncology | Apr 2027 |
| NCT05102721 | Avelumab | Phase 1 | Metastatic Pancreatic Adenocarcinoma | Oncology | Dec 2028 |
| NCT05102721 | Pepinemab | Phase 1 | Metastatic Pancreatic Adenocarcinoma | Oncology | Dec 2028 |
| NCT03769155 | Pepinemab | Phase 1 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Oncology | Dec 2032 |
Cash of $1m on 2024-12-31; operating cash outflow about $16m a year; runway about 1 months at that burn, to Jan 2025
AstraZeneca Pfizer IO Biotech ImmuneOncia Therapeutics Akeso Roche Biotheus Suzhou Suncadia Biopharmaceuticals Shine-On Biomedical 3D Medicines (Sichuan)
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.